Selected research
Industry Research
DTaP and Tdap Vaccines Industry Research Report 2026
Market perspective
The global DTaP and Tdap Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for DTaP and Tdap Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for DTaP and Tdap Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for DTaP and Tdap Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of DTaP and Tdap Vaccines include Johnson & Johnson, Novartis AG, Lanzhou Institute of Biological Products Co., Ltd, Pfizer Inc, GlaxoSmithKline, AstraZeneca, Seqirus, Sanofi Pasteur and Protein Sciences Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global DTaP and Tdap Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
DTaP and Tdap Vaccines Market by Company
Johnson & Johnson
Novartis AG
Lanzhou Institute of Biological Products Co., Ltd
Pfizer Inc
GlaxoSmithKline
AstraZeneca
Seqirus
Sanofi Pasteur
Protein Sciences Corporation
Merck Sharp & Dohme Corp
Emergent BioSolutions Inc
Astellas Pharma US, Inc
DTaP and Tdap Vaccines Segment by Type
Tdap
DTaP
Td
DTaP and Tdap Vaccines Segment by Application
Adult
Pediatric
DTaP and Tdap Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DTaP and Tdap Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of DTaP and Tdap Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DTaP and Tdap Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of DTaP and Tdap Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of DTaP and Tdap Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tdap
- DTaP
- Td
Applications
- Adult
- Pediatric
Companies covered
- Johnson & Johnson
- Novartis AG
- Lanzhou Institute of Biological Products Co., Ltd
- Pfizer Inc
- GlaxoSmithKline
- AstraZeneca
- Seqirus
- Sanofi Pasteur
- Protein Sciences Corporation
- Merck Sharp & Dohme Corp
- Emergent BioSolutions Inc
- Astellas Pharma US, Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global DTaP and Tdap Vaccines Market Size (2021-2032)
- 2.2.2 Global DTaP and Tdap Vaccines Sales (2021-2032)
- 2.2.3 Global DTaP and Tdap Vaccines Market Average Price (2021-2032)
- 2.3 DTaP and Tdap Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tdap
- 2.3.3 DTaP
- 2.3.4 Td
- 2.4 DTaP and Tdap Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adult
- 2.4.3 Pediatric
3 Market Competitive Landscape by Manufacturers
- 3.1 Global DTaP and Tdap Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global DTaP and Tdap Vaccines Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global DTaP and Tdap Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global DTaP and Tdap Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global DTaP and Tdap Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of DTaP and Tdap Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of DTaP and Tdap Vaccines, Product Type & Application
- 3.8 Global Manufacturers of DTaP and Tdap Vaccines, Established Date
- 3.9 Global DTaP and Tdap Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson DTaP and Tdap Vaccines Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Novartis AG
- 4.2.1 Novartis AG Company Information
- 4.2.2 Novartis AG Business Overview
- 4.2.3 Novartis AG DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis AG DTaP and Tdap Vaccines Product Portfolio
- 4.2.5 Novartis AG Recent Developments
- 4.3 Lanzhou Institute of Biological Products Co., Ltd
- 4.3.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
- 4.3.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
- 4.3.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolio
- 4.3.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
- 4.4 Pfizer Inc
- 4.4.1 Pfizer Inc Company Information
- 4.4.2 Pfizer Inc Business Overview
- 4.4.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Inc DTaP and Tdap Vaccines Product Portfolio
- 4.4.5 Pfizer Inc Recent Developments
- 4.5 GlaxoSmithKline
- 4.5.1 GlaxoSmithKline Company Information
- 4.5.2 GlaxoSmithKline Business Overview
- 4.5.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolio
- 4.5.5 GlaxoSmithKline Recent Developments
- 4.6 AstraZeneca
- 4.6.1 AstraZeneca Company Information
- 4.6.2 AstraZeneca Business Overview
- 4.6.3 AstraZeneca DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca DTaP and Tdap Vaccines Product Portfolio
- 4.6.5 AstraZeneca Recent Developments
- 4.7 Seqirus
- 4.7.1 Seqirus Company Information
- 4.7.2 Seqirus Business Overview
- 4.7.3 Seqirus DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Seqirus DTaP and Tdap Vaccines Product Portfolio
- 4.7.5 Seqirus Recent Developments
- 4.8 Sanofi Pasteur
- 4.8.1 Sanofi Pasteur Company Information
- 4.8.2 Sanofi Pasteur Business Overview
- 4.8.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolio
- 4.8.5 Sanofi Pasteur Recent Developments
- 4.9 Protein Sciences Corporation
- 4.9.1 Protein Sciences Corporation Company Information
- 4.9.2 Protein Sciences Corporation Business Overview
- 4.9.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolio
- 4.9.5 Protein Sciences Corporation Recent Developments
- 4.10 Merck Sharp & Dohme Corp
- 4.10.1 Merck Sharp & Dohme Corp Company Information
- 4.10.2 Merck Sharp & Dohme Corp Business Overview
- 4.10.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolio
- 4.10.5 Merck Sharp & Dohme Corp Recent Developments
- 4.11 Emergent BioSolutions Inc
- 4.11.1 Emergent BioSolutions Inc Company Information
- 4.11.2 Emergent BioSolutions Inc Business Overview
- 4.11.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolio
- 4.11.5 Emergent BioSolutions Inc Recent Developments
- 4.12 Astellas Pharma US, Inc
- 4.12.1 Astellas Pharma US, Inc Company Information
- 4.12.2 Astellas Pharma US, Inc Business Overview
- 4.12.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolio
- 4.12.5 Astellas Pharma US, Inc Recent Developments
5 Global DTaP and Tdap Vaccines Market Scenario by Region
- 5.1 Global DTaP and Tdap Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global DTaP and Tdap Vaccines Sales by Region: 2021-2032
- 5.2.1 Global DTaP and Tdap Vaccines Sales by Region: 2021-2026
- 5.2.2 Global DTaP and Tdap Vaccines Sales by Region: 2027-2032
- 5.3 Global DTaP and Tdap Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global DTaP and Tdap Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global DTaP and Tdap Vaccines Revenue by Region: 2027-2032
- 5.4 North America DTaP and Tdap Vaccines Market Facts & Figures by Country
- 5.4.1 North America DTaP and Tdap Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America DTaP and Tdap Vaccines Sales by Country (2021-2032)
- 5.4.3 North America DTaP and Tdap Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe DTaP and Tdap Vaccines Market Facts & Figures by Country
- 5.5.1 Europe DTaP and Tdap Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe DTaP and Tdap Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe DTaP and Tdap Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific DTaP and Tdap Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific DTaP and Tdap Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific DTaP and Tdap Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific DTaP and Tdap Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America DTaP and Tdap Vaccines Market Facts & Figures by Country
- 5.7.1 South America DTaP and Tdap Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America DTaP and Tdap Vaccines Sales by Country (2021-2032)
- 5.7.3 South America DTaP and Tdap Vaccines Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa DTaP and Tdap Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa DTaP and Tdap Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa DTaP and Tdap Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa DTaP and Tdap Vaccines Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global DTaP and Tdap Vaccines Sales by Type (2021-2032)
- 6.1.1 Global DTaP and Tdap Vaccines Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global DTaP and Tdap Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global DTaP and Tdap Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global DTaP and Tdap Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global DTaP and Tdap Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global DTaP and Tdap Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global DTaP and Tdap Vaccines Sales by Application (2021-2032)
- 7.1.1 Global DTaP and Tdap Vaccines Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global DTaP and Tdap Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global DTaP and Tdap Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global DTaP and Tdap Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global DTaP and Tdap Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global DTaP and Tdap Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 DTaP and Tdap Vaccines Value Chain Analysis
- 8.1.1 DTaP and Tdap Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 DTaP and Tdap Vaccines Production Mode & Process
- 8.2 DTaP and Tdap Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 DTaP and Tdap Vaccines Distributors
- 8.2.3 DTaP and Tdap Vaccines Customers
9 Global DTaP and Tdap Vaccines Analyzing Market Dynamics
- 9.1 DTaP and Tdap Vaccines Industry Trends
- 9.2 DTaP and Tdap Vaccines Industry Drivers
- 9.3 DTaP and Tdap Vaccines Industry Opportunities and Challenges
- 9.4 DTaP and Tdap Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst